PATH

Seattle, WA, United States
Seattle, WA, United States
SEARCH FILTERS
Time filter
Source Type

News Article | June 7, 2017
Site: www.prnewswire.co.uk

This action follows a global campaign led by PATH, an international global health nonprofit organization, to make oxygen more accessible in low- and middle-income countries. This effort is designed to reduce preventable newborn, child, and maternal deaths and accelerate progress toward the Sustainable Development Goals laid out by the United Nations in 2015. Previously, oxygen was listed only for use as an inhalational medicine in general anesthesia in the EML and EMLc. PATH reviewed the national essential medicines lists of 105 countries and found that approximately a third (31 percent) did not include oxygen and roughly half (48 percent) listed oxygen only by anesthetic indication. PATH and medical experts petitioned the WHO EML secretariat to include an additional listing of oxygen as a medical gas, extending its use for the management of hypoxemia. This change clarifies oxygen's importance as a medical treatment that should be widely available in health facilities everywhere. Oxygen therapy can save lives, especially for those most vulnerable: newborns, children, and pregnant women. Oxygen is needed for the 1.5 to 2.7 million young children worldwide needing care for severe or very severe pneumonia each year. "Oxygen therapy is an essential component of comprehensive pneumonia treatment for children and now is the time to invest in expanding access to pulse oximetry and oxygen," said Dr. Keith Klugman, director of the pneumonia team at the Bill & Melinda Gates Foundation. "This welcome update to global policy provides an ideal time to reflect on what is needed at national and subnational levels to ensure equitable access to oxygen for all sick children." Oxygen is an essential part of a complete health care system, and is a required treatment for a range of conditions across disciplines and age groups. However, its availability varies widely by level of health facility and region in low- and middle-income countries, and is often hindered by inadequate provider training and a scarcity of necessary equipment and supplies. In particular, facilities often lack pulse oximeters to diagnose and monitor hypoxemia; oxygen sources such as concentrators and cylinders; and devices to deliver therapy, such as cannulas (or small tubing), ventilators, and continuous positive airway pressure equipment. "Accessing oxygen therapy for childhood pneumonia and other indications should not be a matter of location or luck," said Carolyn Reynolds, vice president for Policy and Advocacy at PATH. "We applaud WHO's decision to elevate oxygen as an essential commodity for newborn, child, and maternal health. Now is the time for countries around the world to act on this evidence, which can save thousands of children's and women's lives each year." PATH is implementing a comprehensive approach to increase access to oxygen in low- and middle-income countries, including supporting normative policy change by WHO, helping strengthen markets for oxygen concentrators and pulse oximeters, raising awareness about the importance of oxygen through its HO PE: Oxygen Gives Life campaign, partnering with the United for Oxygen alliance, and developing materials to help advocates and policymakers drive change at the national level. "The updated EML and EMLc emphasize oxygen's lifesaving role and support UNICEF's ongoing work to ensure access to oxygen and pulse oximetry in countries with a high burden of child mortality, such as Kenya," says Dr. Hayalnesh Tarekegn, child health program officer, UNICEF. "It is imperative for countries to align their policies with the latest WHO guidance and implement broader oxygen access for the thousands of children in health facilities that need oxygen to survive." PATH is the leader in global health innovation. An international nonprofit organization, we save lives and improve health, especially among women and children. We accelerate innovation across five platforms—vaccines, drugs, diagnostics, devices, and system and service innovation—that harness our entrepreneurial insight, scientific and public health expertise, and passion for health equity. By mobilizing partners around the world, we take innovation to scale, working alongside countries primarily in Africa and Asia to tackle their greatest health needs. Together, we deliver measureable results that disrupt the cycle of poor health. Learn more at www.path.org.


News Article | June 7, 2017
Site: www.prnewswire.com

PATH and medical experts petitioned the WHO EML secretariat to include an additional listing of oxygen as a medical gas, extending its use for the management of hypoxemia. This change clarifies oxygen's importance as a medical treatment that should be widely available in health facilities everywhere. Oxygen therapy can save lives, especially for those most vulnerable: newborns, children, and pregnant women. Oxygen is needed for the 1.5 to 2.7 million young children worldwide needing care for severe or very severe pneumonia each year. "Oxygen therapy is an essential component of comprehensive pneumonia treatment for children and now is the time to invest in expanding access to pulse oximetry and oxygen," said Dr. Keith Klugman, director of the pneumonia team at the Bill & Melinda Gates Foundation. "This welcome update to global policy provides an ideal time to reflect on what is needed at national and subnational levels to ensure equitable access to oxygen for all sick children." Oxygen is an essential part of a complete health care system, and is a required treatment for a range of conditions across disciplines and age groups. However, its availability varies widely by level of health facility and region in low- and middle-income countries, and is often hindered by inadequate provider training and a scarcity of necessary equipment and supplies. In particular, facilities often lack pulse oximeters to diagnose and monitor hypoxemia; oxygen sources such as concentrators and cylinders; and devices to deliver therapy, such as cannulas (or small tubing), ventilators, and continuous positive airway pressure equipment. "Accessing oxygen therapy for childhood pneumonia and other indications should not be a matter of location or luck," said Carolyn Reynolds, vice president for Policy and Advocacy at PATH. "We applaud WHO's decision to elevate oxygen as an essential commodity for newborn, child, and maternal health. Now is the time for countries around the world to act on this evidence, which can save thousands of children's and women's lives each year." PATH is implementing a comprehensive approach to increase access to oxygen in low- and middle-income countries, including supporting normative policy change by WHO, helping strengthen markets for oxygen concentrators and pulse oximeters, raising awareness about the importance of oxygen through its HO PE: Oxygen Gives Life campaign, partnering with the United for Oxygen alliance, and developing materials to help advocates and policymakers drive change at the national level. "The updated EML and EMLc emphasize oxygen's lifesaving role and support UNICEF's ongoing work to ensure access to oxygen and pulse oximetry in countries with a high burden of child mortality, such as Kenya," says Dr. Hayalnesh Tarekegn, child health program officer, UNICEF. "It is imperative for countries to align their policies with the latest WHO guidance and implement broader oxygen access for the thousands of children in health facilities that need oxygen to survive." PATH is the leader in global health innovation. An international nonprofit organization, we save lives and improve health, especially among women and children. We accelerate innovation across five platforms—vaccines, drugs, diagnostics, devices, and system and service innovation—that harness our entrepreneurial insight, scientific and public health expertise, and passion for health equity. By mobilizing partners around the world, we take innovation to scale, working alongside countries primarily in Africa and Asia to tackle their greatest health needs. Together, we deliver measureable results that disrupt the cycle of poor health. Learn more at www.path.org. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-who-designation-for-oxygen-could-save-thousands-of-lives-globally-300470127.html


News Article | June 7, 2017
Site: en.prnasia.com

Additional listing for oxygen on the Model List of Essential Medicines part of broader effort by PATH and other organizations to improve global health by making oxygen more accessible SEATTLE, June 7, 2017 /PRNewswire/ -- PATH hailed a landmark decision this week by the World Health Organization (WHO) to include a new indication for oxygen in its Model List of Essential Medicines (EML) and List of Essential Medicines for Children (EMLc), identifying oxygen as a medicine essential for the management of hypoxemia. Hypoxemia, or dangerously low levels of oxygen in the blood, can be fatal without oxygen therapy. Without oxygen, it would be next to impossible to treat hypoxemia resulting from conditions such as pneumonia, which is the leading cause of mortality in children under five. The WHO action could reduce child deaths from pneumonia by 35 percent annually in high-burden settings. This action follows a global campaign led by PATH, an international global health nonprofit organization, to make oxygen more accessible in low- and middle-income countries. This effort is designed to reduce preventable newborn, child, and maternal deaths and accelerate progress toward the Sustainable Development Goals laid out by the United Nations in 2015. Previously, oxygen was listed only for use as an inhalational medicine in general anesthesia in the EML and EMLc. PATH reviewed the national essential medicines lists of 105 countries and found that approximately a third (31 percent) did not include oxygen and roughly half (48 percent) listed oxygen only by anesthetic indication. PATH and medical experts petitioned the WHO EML secretariat to include an additional listing of oxygen as a medical gas, extending its use for the management of hypoxemia. This change clarifies oxygen's importance as a medical treatment that should be widely available in health facilities everywhere. Oxygen therapy can save lives, especially for those most vulnerable: newborns, children, and pregnant women. Oxygen is needed for the 1.5 to 2.7 million young children worldwide needing care for severe or very severe pneumonia each year. "Oxygen therapy is an essential component of comprehensive pneumonia treatment for children and now is the time to invest in expanding access to pulse oximetry and oxygen," said Dr. Keith Klugman, director of the pneumonia team at the Bill & Melinda Gates Foundation. "This welcome update to global policy provides an ideal time to reflect on what is needed at national and subnational levels to ensure equitable access to oxygen for all sick children." Oxygen is an essential part of a complete health care system, and is a required treatment for a range of conditions across disciplines and age groups. However, its availability varies widely by level of health facility and region in low- and middle-income countries, and is often hindered by inadequate provider training and a scarcity of necessary equipment and supplies. In particular, facilities often lack pulse oximeters to diagnose and monitor hypoxemia; oxygen sources such as concentrators and cylinders; and devices to deliver therapy, such as cannulas (or small tubing), ventilators, and continuous positive airway pressure equipment. "Accessing oxygen therapy for childhood pneumonia and other indications should not be a matter of location or luck," said Carolyn Reynolds, vice president for Policy and Advocacy at PATH. "We applaud WHO's decision to elevate oxygen as an essential commodity for newborn, child, and maternal health. Now is the time for countries around the world to act on this evidence, which can save thousands of children's and women's lives each year." PATH is implementing a comprehensive approach to increase access to oxygen in low- and middle-income countries, including supporting normative policy change by WHO, helping strengthen markets for oxygen concentrators and pulse oximeters, raising awareness about the importance of oxygen through its HO PE: Oxygen Gives Life campaign, partnering with the United for Oxygen alliance, and developing materials to help advocates and policymakers drive change at the national level. "The updated EML and EMLc emphasize oxygen's lifesaving role and support UNICEF's ongoing work to ensure access to oxygen and pulse oximetry in countries with a high burden of child mortality, such as Kenya," says Dr. Hayalnesh Tarekegn, child health program officer, UNICEF. "It is imperative for countries to align their policies with the latest WHO guidance and implement broader oxygen access for the thousands of children in health facilities that need oxygen to survive." PATH is the leader in global health innovation. An international nonprofit organization, we save lives and improve health, especially among women and children. We accelerate innovation across five platforms--vaccines, drugs, diagnostics, devices, and system and service innovation--that harness our entrepreneurial insight, scientific and public health expertise, and passion for health equity. By mobilizing partners around the world, we take innovation to scale, working alongside countries primarily in Africa and Asia to tackle their greatest health needs. Together, we deliver measurable results that disrupt the cycle of poor health. Learn more at www.path.org.


News Article | September 18, 2017
Site: www.prweb.com

A multisectoral partnership today launched a first-of-its-kind global coalition dedicated to increasing access to essential medicines and health products to prevent and treat noncommunicable diseases (NCDs) and conditions, including diabetes, hypertension, and cardiovascular disease. The new Coalition for Access to NCD Medicines & Products brings together governments, the private sector, philanthropic and academic institutions, and nongovernmental organizations to tackle barriers countries face in procuring, supplying, and distributing essential medicines and technologies and ensuring they are used effectively. PATH will serve as the coalition secretariat. The coalition will partner with countries to help them achieve the World Health Organization target of 80 percent availability of affordable technologies and essential medicines, including generics, required to treat NCDs in both public and private facilities. The launch event, alongside the United Nations General Assembly in New York, features an interactive panel of global health leaders and influencers from across sectors sharing their perspectives on the opportunities ahead to reduce the toll of NCDs. Panel speakers include Peter Singer, CEO of Grand Challenges Canada; Sir George Alleyne, director emeritus, Pan American Health Organization; Khawar Mann, partner with the Abraaj Group; Rebecca Martin, director of the Center for Global Health at the US Centers for Disease Control and Prevention; Jean Claude Mbanya, professor of medicine and endocrinology at the University of Yaoundé in Cameroon; and Sania Nishtar, founder and president of Heartfile. “Medicines and technologies for chronic diseases are less available and less affordable for people in low-resource countries,” said Steve Davis, PATH president and CEO. “That equity gap leaves the most vulnerable people at greater risk for complications and death from NCDs. We can close the gap by ensuring that innovative new tools and existing technologies are within reach for people who need them, regardless of where they live.” NCDs are the number one cause of death and disability worldwide. About three-quarters of NCD-related deaths occur in low- and middle-income countries, and it is estimated that 100 million people in low-resource settings are forced into poverty each year by the costs associated with managing chronic diseases. The coalition is unique in several ways, from its multisectoral approach of engaging stakeholders across sectors at all levels to its focus on increasing access to medicines and products and providing technical and advocacy expertise both at the country and global levels. “We know from our work with health facilities, pharmacies, care providers, and patients that many people with diabetes and cardiovascular disease are not able to access the medicines and products they need at a price they can afford,” said Dr. Kibachio Joseph, head, noncommunicable disease unit, Ministry of Health, Republic of Kenya. “This coalition will add great momentum to the government of Kenya’s ongoing efforts to ensure that people can access the treatment they need.” Progress on reducing the burden of NCDs has been slow and uneven within and across countries. Some of the issues affecting access to medicines and products include inefficient procurement practices, inadequate funding models, and pricing mark-ups along the supply chain. Coalition members will focus specifically on strengthening health systems and the supply chain for essential medicines and products, financing and costing issues, and advocacy. “By leveraging the skills, resources, and expertise of members, the coalition will complement existing initiatives, create new opportunities, and raise awareness about the importance of ensuring equal access to health commodities for NCDs,” said Helen McGuire, leader of PATH’s NCD program. “Together, we can identify and address barriers to access, strengthen supply chains, control the risk of interruptions or delays, and efficiently get products to market.” The work builds on efforts by PATH and other founding members that have been laying the groundwork for the coalition for several years. Health coalitions on reproductive health, tuberculosis, and HIV/AIDS have successfully used a similar approach to strengthen supply chains and reduce financial burdens on individual and national budgets. The coalition includes the following member organizations: Ministry of Health, Republic of Kenya Ministry of Health & Social Action, Republic of Senegal Ministry of Health, Republic of Uganda NCD Alliance Novo Nordisk PATH (secretariat) Pfizer, Inc. RTI International World Heart Federation NCD Child International Pediatric Association World Hypertension League International Federation of Pharmaceutical Manufacturers & Associations Teva Pharmaceutical Industries Ltd. Merck KGaA, Darmstadt, Germany Key funders of the coalition include Novo Nordisk, PATH, and Pfizer, Inc. PATH is the leader in global health innovation. An international nonprofit organization, PATH saves lives and improves health, especially among women and children. PATH accelerates innovation across five platforms—vaccines, drugs, diagnostics, devices, and system and service innovations—that harness our entrepreneurial insight, scientific and public health expertise, and passion for health equity. By mobilizing partners around the world, PATH takes innovation to scale, working alongside countries primarily in Africa and Asia to tackle their greatest health needs. With these key partners, PATH delivers measurable results that disrupt the cycle of poor health. Learn more at http://www.path.org.


News Article | November 10, 2016
Site: www.eurekalert.org

Project led By University of Maryland School of Medicine will focus on accelerating the use of vaccines to protect from disease that kills more than 220,000 annually Baltimore, MD, November 10, 2016 - Typhoid fever, a bacterial infection that causes high fever and other disabling symptoms, remains a serious global problem in the developing world: it kills almost a quarter of a million people annually, and infects about 21 million. To help speed the introduction of, and access to, new and more effective typhoid vaccines, the University of Maryland School of Medicine (UM SOM) Center for Vaccine Development (CVD) has received a grant of $36.9 million from the Bill & Melinda Gates Foundation. The project, known as Typhoid Vaccine Acceleration Consortium (TyVAC), is a partnership with the Oxford Vaccine Group at the University of Oxford and PATH, an international nonprofit global health organization based in Seattle. TyVAC will focus on conjugate vaccines, which can trigger a stronger immune response in certain vulnerable populations, such as infants and children, than current typhoid vaccines. TyVAC will employ a multidisciplinary approach to study and control typhoid, and generate evidence that informs global policies. The project will work closely with governments and policymakers to introduce vaccines in lower-income countries with a high burden of typhoid. The effort will also examine how well the vaccine rollouts work in early adopter countries. The project's overall goal is to support accelerated, evidence-based decisions for new typhoid conjugate vaccine introductions that will significantly reduce the severe health and economic burdens of the disease. "Typhoid fever disproportionately impacts children and poor populations," said Kathleen Neuzil, MD, MPH, FIDSA, professor of medicine at UM SOM, director of CVD, and deputy director of the Institute for Global Health (IGH). "With our long history of work in typhoid and typhoid vaccines, we look forward to working with partners to catalyze action against this significant public health problem." "It is unconscionable that children are still dying by the thousands every year from diseases like typhoid that are completely preventable," said Anita Zaidi, director of the Enteric and Diarrheal Diseases team at the Bill & Melinda Gates Foundation. "The prevention and control of typhoid should be a global health priority and we are pleased to support the Typhoid Vaccine Acceleration Consortium as part of our overall strategy to combat typhoid through an integrated approach including access to clean water, improved sanitation, and immunization." At present, the currently available vaccines for typhoid fever are underutilized despite the substantial disease burden and a World Health Organization recommendation for the use of typhoid vaccines in areas of high burden. Typhoid conjugate vaccines have the promise to overcome some of the barriers of the currently available vaccines, providing a stronger immune response, a longer duration of protection, and the ability to be incorporated into the routine vaccination schedule targeted at children less than two years old. "We are excited to work in partnership with CVD to bring our expertise on typhoid infections and vaccines to the consortium and improve health through TyVAC," said Andrew Pollard, MD, PhD, professor of pediatric infection and immunity at the University of Oxford, and director of the Oxford Vaccine Group. Population density, limited sanitation, and poor water quality can provide a breeding ground for typhoid. "With increasing urbanization, we could see an even greater burden of typhoid," noted Deborah Atherly, PhD, head of Policy, Access, and Introduction for PATH's Center for Vaccine Innovation and Access. "Through TyVAC, we will work to ensure that typhoid vaccines finally reach those who need them most." "Typhoid is a significant public health problem in many parts of the world," said UM SOM Dean E. Albert Reece, MD, PhD, MBA, who is also vice president for medical affairs at the University of Maryland and the John Z. and Akiko K. Bowers Distinguished Professor. "Over several decades, the CVD has helped save millions of lives. This generous grant from the Gates Foundation will allow our scientists, working with national and international partners, to continue with this crucial work." The CVD at the University of Maryland School of Medicine works nationally and internationally to prevent disease and save lives through the development and delivery of vaccines. As an academic research center, CVD is engaged in the full range of vaccinology, including basic science research, vaccine development, pre-clinical and clinical evaluation, and post-marketing field studies. Learn more at http://medschool. . The University of Maryland School of Medicine was chartered in 1807 and is the first public medical school in the United States and continues today as an innovative leader in accelerating innovation and discovery in medicine. The School of Medicine is the founding school of the University of Maryland and is an integral part of the 11-campus University System of Maryland. Located on the University of Maryland's Baltimore campus, the School of Medicine works closely with the University of Maryland Medical Center and Medical System to provide a research-intensive, academic and clinically based education. With 43 academic departments, centers and institutes and a faculty of more than 3,000 physicians and research scientists plus more than $400 million in extramural funding, the School is regarded as one of the leading biomedical research institutions in the U.S. with top-tier faculty and programs in cancer, brain science, surgery and transplantation, trauma and emergency medicine, vaccine development and human genomics, among other centers of excellence. The School is not only concerned with the health of the citizens of Maryland and the nation, but also has a global presence, with research and treatment facilities in more than 35 countries around the world. Learn more at http://medschool. . The University of Oxford is one of the top five higher education institutions in the world and hosts the Oxford Vaccine Group (OVG) in the Department of Paediatrics (http://www. ). OVG is a vaccine design, development, clinical trials, and laboratory evaluation research group with specific expertise in vaccine evaluation in paediatric populations. The University of Oxford has strategically made a major investment in infrastructure to support research on vaccines and immunity over the past two decades. The OVG is one of the largest academic research groups in the world focused on designing, developing, and evaluating vaccines for children, as well as characterizing immune response to vaccines and infectious diseases. PATH is the leader in global health innovation. An international nonprofit organization, we save lives and improve health, especially among women and children. We accelerate innovation across five platforms--vaccines, drugs, diagnostics, devices, and system and service innovations--that harness our entrepreneurial insight, scientific and public health expertise, and passion for health equity. By mobilizing partners around the world, we take innovation to scale, working alongside countries primarily in Africa and Asia to tackle their greatest health needs. Together, we deliver measurable results that disrupt the cycle of poor health. Learn more at http://www.


Tate J.E.,Centers for Disease Control and Prevention | Burton A.H.,WHO | Boschi-Pinto C.,WHO | Steele A.D.,PATH | And 2 more authors.
The Lancet Infectious Diseases | Year: 2012

Background: WHO recommends routine use of rotavirus vaccines in all countries, particularly in those with high mortality attributable to diarrhoeal diseases. To establish the burden of life-threatening rotavirus disease before the introduction of a rotavirus vaccine, we aimed to update the estimated number of deaths worldwide in children younger than 5 years due to diarrhoea attributable to rotavirus infection. Methods: We used PubMed to identify studies of at least 100 children younger than 5 years who had been admitted to hospital with diarrhoea. Additionally, we required the studies to have a data collection midpoint of the year 2000 or later, to be done in full-year increments, and to assesses diarrhoea attributable to rotavirus with EIAs or polyacrylamide gel electrophoresis. We also included data from countries that participated in the WHO-coordinated Global Rotavirus Surveillance Network (consisting of participating member states during 2009) and that met study criteria. For countries that have introduced a rotavirus vaccine into their national immunisation programmes, we excluded data subsequent to the introduction. We classified studies into one of five groups on the basis of region and the level of child mortality in the country in which the study was done. For each group, to obtain estimates of rotavirus-associated mortality, we multiplied the random-effect mean rotavirus detection rate by the 2008 diarrhoea-related mortality figures for countries in that group. We derived the worldwide mortality estimate by summing our regional estimates. Findings: Worldwide in 2008, diarrhoea attributable to rotavirus infection resulted in 453 000 deaths (95% CI 420 000-494 000) in children younger than 5 years-37% of deaths attributable to diarrhoea and 5% of all deaths in children younger than 5 years. Five countries accounted for more than half of all deaths attributable to rotavirus infection: Democratic Republic of the Congo, Ethiopia, India, Nigeria, and Pakistan; India alone accounted for 22% of deaths (98 621 deaths). Interpretation: Introduction of effective and available rotavirus vaccines could substantially affect worldwide deaths attributable to diarrhoea. Our new estimates can be used to advocate for rotavirus vaccine introduction and to monitor the effect of vaccination on mortality once introduced. Funding: None. © 2012 Elsevier Ltd.


News Article | November 16, 2016
Site: www.eurekalert.org

Seattle, November 16, 2016 --Self-injection of the contraceptive Sayana® Press is both feasible and highly acceptable among women participating in the first such research study conducted in sub-Saharan Africa, according to results published online by the journal Contraception. Sayana Press is an all-in-one injectable contraceptive that puts control of women's health in their hands. It is a subcutaneous formulation of the widely used injectable contraceptive depot medroxyprogesterone acetate (DMPA-SC) delivered in the PATH-developed Uniject™ injection system. "This pioneering research is important not only for the women of Uganda, but for all women," says Professor Dr. Anthony K. Mbonye, Acting Director General, Health Services, Ministry of Health, and co-investigator of the study. "The evidence that women can self-inject safely and successfully can help inform family planning program decision-making in countries around the world." In low- and middle-income regions of the world, nearly 225 million women want to plan their pregnancies but don't have access to a method that meets the reality of their lives. Expanding access to new contraceptive options such as Sayana Press can improve health and save lives by allowing women to delay or space their births. "Many women don't have the power to plan their families, because health centers are far away or partners refuse to support them to use contraceptives," explains Fiona Walugembe, PATH's Sayana Press coordinator in Uganda. "Self-injection gives women an additional option that increases both convenience and privacy." Sayana Press combines one dose of the contraceptive and a single-use needle in the Uniject device. Its streamlined design makes it small, light, and easy to use. It requires minimal training to use, making it especially suitable for community-based distribution--and for women to administer themselves through self-injection. Provider-administered Sayana Press is being offered as a family planning option in several countries around the world, including Uganda. Sayana Press is manufactured by Pfizer Inc. and Uniject is manufactured by BD. PATH first developed the Uniject injection system in the 1980s to make injections simpler and safer in low-resource settings. PATH and the Uganda Ministry of Health collected the newly published results to determine if Ugandan women liked the option and could inject themselves successfully, remember their reinjection dates, and safely store and dispose of the device--evidence critical for family planning decision-makers in low-income countries considering integration of self-injection in their programs. In the Uganda study, 380 women between the ages of 18 and 45 were trained by licensed nurses to self-inject Sayana Press, guided by a client instruction booklet. Those considered to be competent (98 percent) were given a Sayana Press device, instruction booklet, and reinjection calendar for self-injection at home three months later. Shortly after the participants' scheduled reinjection dates, nurses visited participants at home to learn whether they had reinjected on time and to observe their self-injection technique on a model. At this follow-up, 88 percent of participants demonstrated injection competence and 98 percent of those who self-injected expressed the desire to continue self-injecting. A similar study in Senegal was just completed. The studies build on previous self-injection research conducted in the United States and Europe. Self-injection of Sayana Press has been approved by the United Kingdom Medicines & Healthcare products Regulatory Agency and is under regulatory review in several other countries. While these approvals open the door for introduction of self-injection, further evidence is needed to guide family planning program decisions. Dr. Jane Cover, PATH Sayana Press Research Manager, puts the new Uganda study results in context: "Regulatory approval is necessary but not sufficient to make a new product or practice available to people in communities," she explains. "We have heard clearly from ministries of health in several African countries that they want more evidence on whether and how self-injection would work in their contexts. That evidence is starting to emerge with these first promising results from Uganda." Sayana Press injections are already widely available from family planning providers in many countries. For example, since 2014, nearly 500,000 doses of Sayana Press have been provided by health workers through country-led pilot introductions in Burkina Faso, Niger, Senegal, and Uganda, coordinated by PATH. These four countries are now moving forward with scale-up of provider-administered Sayana Press in their national family planning programs. Given the successful introduction of Sayana Press administered by community health workers and these promising self-injection research results, the Uganda Ministry of Health has begun offering Sayana Press self-injection as an option for women in Uganda's Mubende District--the first time the practice has been available in sub-Saharan Africa outside of a research setting. This month, PATH and the Mubende District Health Team trained approximately 100 health care providers at public-sector facilities to teach clients how to self-inject. The providers will offer Sayana Press as one family planning option, either by administering the injection or supporting clients to self-inject, according to their preference. The Uganda Ministry of Health and PATH hope to expand self-injection in the country in 2017. Sayana Press and Depo-Provera are registered trademarks of Pfizer Inc. Uniject is a trademark of BD. PATH is the leader in global health innovation. An international nonprofit organization, PATH saves lives and improves health, especially among women and children. PATH accelerates innovation across five platforms--vaccines, drugs, diagnostics, devices, and system and service innovations--that harness our entrepreneurial insight, scientific and public health expertise, and passion for health equity. By mobilizing partners around the world, PATH takes innovation to scale, working alongside countries primarily in Africa and Asia to tackle their greatest health needs. With these key partners, PATH delivers measurable results that disrupt the cycle of poor health. Learn more at http://www. .


McAdams D.,PATH
Expert review of vaccines | Year: 2012

Research on spray drying as a processing method to improve vaccine stabilization and to enable novel routes of vaccine delivery has produced promising results; however, the method has yet to be adopted for the manufacture of vaccine products by the pharmaceutical industry. This article reviews the status of spray-drying technology and discusses barriers and opportunities for its future application to vaccines.


Despite improvements to water quality, sanitation, and the implementation of current prevention and treatment interventions, diarrhea remains a major cause of illness and death, especially among children less than five years of age in the developing world. Rotavirus vaccines have already begun making a real impact on diarrhea, but several more enteric vaccines will be necessary to achieve broader reductions of illness and death. Among the many causes of diarrheal disease, enterotoxigenic Escherichia coli (ETEC) and Shigella are the two most important bacterial pathogens for which there are no currently licensed vaccines. Vaccines against these two pathogens could greatly reduce the impact of disease caused by these infections. This review describes the approaches to ETEC and Shigella vaccines that are currently under development, including a range of both cellular and subunit approaches for each pathogen. In addition, the review discusses strategies for maximizing the potential benefit of these vaccines, which includes the feasibility of co-administration, consolidation, and combination of vaccine candidates, as well as issues related to effective administration of enteric vaccines to infants. Recent impact studies indicate that ETEC and Shigella vaccines could significantly benefit global public health. Either vaccine, particularly if they could be combined together or with another enteric vaccine, would be an extremely valuable tool for saving lives and promoting the health of infants and children in the developing world, as well as potentially providing protection to travelers and military personnel visiting endemic areas. © 2014 Elsevier Ltd.


This disclosure is directed to compositions that combine the polysaccharide-specific antibody protection afforded by the conventional vaccines through carrier effects provided by one or more pneumococcal common T-cell antigen(s) together with Streptococcus pneumoniae-specific Th-17 responses elicited by the pneumococcal carrier common T-cell antigen. The disclosed compositions are useful for pan-serotypic protection against NP carriage, and antibody responses against common pneumococcal virulence factors, potentially useful for pan-serotype protection against Streptococcus pneumoniae invasive diseases.

Loading PATH collaborators
Loading PATH collaborators